Point mutation or fusions were infrequently observed in these tumors with a notable exception of PIK3CA. PIK3CA was mutated in 37% of tumor samples (S1A Fig, and when combined with amplifications, 51% of samples had a PIK3CA abnormality (S1B Fig). Here, PIK3CA is linked to neoplasm.